ICON PLC (ICLR): Financial results for Q3 2026
ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. 1 ICON Reports Third Quarter 2026 Results Third Quarter 2026 Key Highlights ▪ Strong commercial performance with net business wins in the quarter of $3,150 million; a net book- to-bill of 1.56 x and closing backlog of $24.5 billion, up 4.8% sequentially. ▪ Revenue of $2,024.8 mil
How this was made
The 30-second read
Why it matters
The earnings release updates revenue guidance and highlights a $400M share buyback, which may affect valuation multiples.
Market read
The new earnings and guidance provide fresh data for investors in the CRO sector and may prompt short‑term price adjustments.
What to watch
The $400M share repurchase and $2.15B bond issuance improve balance sheet strength, which could support a higher valuation.
Background
ICON plc is a world‑leading clinical research organization that filed its Q3 2026 earnings via a SEC Form 6‑K.
Ticker impact
ICON plc reported Q3 2026 results with revenue of $2.0B, adjusted EBITDA $336.9M and updated full-year guidance to $8.1-$8.2B revenue and $10.35-$10.65 EPS.
likely modest pressure as guidance is modest and below prior expectations.
The earnings release is the first public disclosure of these numbers; investors will reprice the stock based on the new guidance and cash flow figures.
Market effects
Provides a data point for the clinical research services sector, indicating modest growth and strong cash generation.
May influence European biotech and CRO stocks as ICON is a Dublin‑based global player.
Limited to investors tracking CROs and biotech service providers worldwide.
Counterpoint
If investors believe the guidance underestimates upside, the stock could rally on the strong cash flow and backlog.
Key entities
- companyICON plc
Clinical research organization reporting Q3 2026 results.